Biosimilars

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports…

Patent dispute settlement with Janssen clears path for biosimilar to Stelara in key global markets

Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim

Dr Reddy's Rituximab biosimilar DRL_RI (ITUXREDI) progresses towards European approval with EMA CHMP endorsement

Strategic shift to Skyrizi and Rinvoq strengthens AbbVie's dominance in immunology despite Humira's biosimilar competition

As more biologics lose patent protection, the influx of biosimilars is set to expand, offering cost-effective alternatives and…

Ranibizumab biosimilar is the company’s seventh biosimilar

By introducing cost-effective drugs for critical illness by leveraging path-breaking manufacturing technologies, India could…

Humira’s 52-week study evaluated adalimumab’s efficacy and safety for moderate-to-severe psoriasis, exploring continuous against…

Manufactured using Enzene Biosciences’ patented Continuous Manufacturing Process, Bevacizumab is a biosimilar to Avastin and will…